This prospective case-control study included 85 patients with lung involvement related to the COVID-19 virus and a group of ...

This programme is designed to advance next-generation vaccines, therapeutics, and other tools to combat Covid-19. The therapeutic, dubbed S-892216, leverages protease inhibitor technology to block ...

Shionogi & Co. Ltd. won a $375 million project agreement from the Rapid Response Partnership Vehicle to develop its 3CL protease inhibitor, S-892216, as a long-acting injectable for COVID-19 ...

However, it "seeks fair compensation for Pfizer's use of a coronavirus 3CL protease inhibitor claimed in the '953 patent." There's a potential third wheel in the dispute, according to SVB ...

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

Announcing a new article publication for BIO Integration journal. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in China in December 2019, rapidly spread worldwide, ...

a protease inhibitor used to treat reflux esophagitis and chronic pancreatitis. The organization is also raising funds to support COVID-related trials of remdesivir, a broad-spectrum antiviral ...

a 3CL protease inhibitor, as a long-acting injectable for COVID-19 pre-exposure prophylaxis. RRPV is a consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part ...

Aligos Therapeutics, Inc.’s ALGS share price has surged by 15.33%, which has investors questioning if this is right time to ...